What End-Users Think About HIV Prevention Products and Multipurpose Prevention Technologies (MPTs)

23 June 2020

The Tablets, Ring, Injections as Options study, or TRIO, was conducted with young women aged 18 to 30 in Kisumu, Kenya and Soshanguve, South Africa between 2015 and 2017. The study examined young women’s perspectives on future MPT in a clinical study of three placebo MPT products. TRIO identified anticipated enablers and barriers to adoption and use of future MPT, explored preferred product characteristics, and solicited novel product design recommendations. The project’s key findings are that women overwhelmingly prefer a 2-in-1 product for pregnancy and HIV prevention, and want a product that will protect them in unanticipated situations. Barriers to product uptake and use identified include side effects, fear of using new biomedical technologies, misunderstandings about use and stigma, and trust within their relationships.

Featured Resources

Document

PrEP Ring for Adolescent Girls and Youth Women: Summary of research findings

This brief outlines findings from a recent study which has published critical new data on use of the dapivirine vaginal ring (PrEP ring or ring) among adolescent girls and young women in eastern and southern Africa, offering evidence that the ring is safe, effective, and highly acceptable.

Presentation

PrEP Ring Safety Data in Adolescent Girls and Youth Women (AGYW)

This slide deck presents emerging evidence to support conversations on expanding pre-exposure prophylaxis (PrEP) ring access for adolescent girls and young women (AGYW) in policy and programmatic rollout.

Document

PrEP Ring for Pregnant and Breastfeeding Women: Summary of research findings in eastern and southern Africa

This brief outlines findings from recent studies which have published critical new data on use of the dapivirine vaginal ring (PrEP ring or ring) among pregnant and breastfeeding people in eastern and southern Africa, offering evidence that the PrEP ring is a safe and effective HIV prevention method for a broader population than was initially…

Presentation

PrEP Ring Safety Data in Pregnant and Breastfeeding Women

This slide deck presents emerging evidence to support conversations on expanding pre-exposure prophylaxis (PrEP) ring access for pregnant and breastfeeding women (PBFW) in policy and programmatic rollout.

Spreadsheet

MOSAIC – PrEP Site Implementation and New Product Readiness Assessment Tool

This tool is intended to provide insight into the current state of PrEP services and to identify critical barriers and facilitators to PrEP implementation. Additionally, this tool is designed to inform preparations for new PrEP product introduction (CAB PrEP, PrEP ring, or both) according to national priorities. Findings from readiness assessment visits using this tool…

PrEP for Pregnant and Breastfeeding People: Advocacy, Policy, and Programmatic Tools

Evidence shows that offering PrEP is a safe and effective HIV prevention strategy for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of PrEP to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that people have an increased need for HIV…

Document

Private Sector Market Assessment: Eswatini

This market assessment explores the opportunities and barriers to leveraging private sector channels to expand access to new and existing pre-exposure prophylaxis (PrEP) methods, including oral PrEP, the dapivirine vaginal ring (PrEP ring), and long acting cabotegravir (CAB PrEP) in Eswatini.

Document

CATALYST Interim Learnings (May-November 2023)

In this first interim analysis, the MOSAIC team provides key learnings from preparing for the delivery of PrEP choice, a summary of challenges experienced in implementing the enhanced service delivery model and the solutions introduced, programmatic considerations for countries preparing to introduce new PrEP methods, and a list of publicly accessible tools and resources used…

Document

Dapivirine Vaginal Ring Clinical Training for Providers

This clinical training, developed by the MOSAIC consortium for use in the CATALYST study, can be used to train providers to offer the dapivirine vaginal ring.

External Link

ICAP PrEP Package for Providers: PrEParing for Choice

ICAP’s PrEP Package for Providers: PrEParing for Choice was developed by ICAP at Columbia University to promote the introduction and implementation of multiple PrEP products. The material is designed to capacitate health care teams with the knowledge and skills to counsel clients about PrEP and PrEP options, conduct effective PrEP initiation visits, and monitor and…